These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37397081)

  • 1. Interpreting Nonrandomized Evidence for Clinical Decision Making in Cardio-Oncology.
    Chatur S; Fu E; Vaduganathan M
    JACC CardioOncol; 2023 Jun; 5(3):329-331. PubMed ID: 37397081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary Cardioprotection Reduces Mortality in Lymphoma Patients with Increased Risk of Anthracycline Cardiotoxicity, Treated by R-CHOP Regimen.
    Długosz-Danecka M; Gruszka AM; Szmit S; Olszanecka A; Ogórka T; Sobociński M; Jaroszyński A; Krawczyk K; Skotnicki AB; Jurczak W
    Chemotherapy; 2018; 63(4):238-245. PubMed ID: 30372698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardio-Oncology: Mechanisms, Drug Combinations, and Reverse Cardio-Oncology.
    Liang Z; He Y; Hu X
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anthracycline-Induced Cardiotoxicity: Time to Focus on Cardioprotection Again.
    Croft AJ; Ngo DTM; Sverdlov AL
    Heart Lung Circ; 2019 Oct; 28(10):1454-1456. PubMed ID: 31495502
    [No Abstract]   [Full Text] [Related]  

  • 5. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology.
    Pudil R; Mueller C; Čelutkienė J; Henriksen PA; Lenihan D; Dent S; Barac A; Stanway S; Moslehi J; Suter TM; Ky B; Štěrba M; Cardinale D; Cohen-Solal A; Tocchetti CG; Farmakis D; Bergler-Klein J; Anker MS; Von Haehling S; Belenkov Y; Iakobishvili Z; Maack C; Ciardiello F; Ruschitzka F; Coats AJS; Seferovic P; Lainscak M; Piepoli MF; Chioncel O; Bax J; Hulot JS; Skouri H; Hägler-Laube ES; Asteggiano R; Fernandez TL; de Boer RA; Lyon AR
    Eur J Heart Fail; 2020 Nov; 22(11):1966-1983. PubMed ID: 33006257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardio-Oncology: Learning From the Old, Applying to the New.
    Abe JI; Yusuf SW; Deswal A; Herrmann J
    Front Cardiovasc Med; 2020; 7():601893. PubMed ID: 33324688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Portrait of Italian Cardio-Oncology: Results of a Nationwide Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) Survey.
    Canale ML; Turazza F; Lestuzzi C; Parrini I; Camerini A; Russo G; Colivicchi F; Gabrielli D; Gulizia MM; Oliva S; Tarantini L; Maurea N; Rigacci L; Petrolati S; Casolo G; Bisceglia I
    Front Cardiovasc Med; 2021; 8():677544. PubMed ID: 34222373
    [No Abstract]   [Full Text] [Related]  

  • 8. Exercise Cardio-Oncology: Exercise as a Potential Therapeutic Modality in the Management of Anthracycline-Induced Cardiotoxicity.
    Kang DW; Wilson RL; Christopher CN; Normann AJ; Barnes O; Lesansee JD; Choi G; Dieli-Conwright CM
    Front Cardiovasc Med; 2021; 8():805735. PubMed ID: 35097024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What Does a Cardio-oncology Service Offer to the Oncologist and the Haematologist?
    Andres MS; Pan J; Lyon AR
    Clin Oncol (R Coll Radiol); 2021 Aug; 33(8):483-493. PubMed ID: 33832839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and proposed framework for shared decision making in cardio-oncology.
    Hull SC; Soufer A; Spatz ES; Baldassarre LA
    Cardiooncology; 2021 Aug; 7(1):30. PubMed ID: 34425913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off.
    Upshaw JN; Ruthazer R; Miller KD; Parsons SK; Erban JK; O'Neill AM; Demissei B; Sledge G; Wagner L; Ky B; Kent DM
    Clin Breast Cancer; 2019 Aug; 19(4):259-267.e1. PubMed ID: 31175052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.
    Lyon AR; Dent S; Stanway S; Earl H; Brezden-Masley C; Cohen-Solal A; Tocchetti CG; Moslehi JJ; Groarke JD; Bergler-Klein J; Khoo V; Tan LL; Anker MS; von Haehling S; Maack C; Pudil R; Barac A; Thavendiranathan P; Ky B; Neilan TG; Belenkov Y; Rosen SD; Iakobishvili Z; Sverdlov AL; Hajjar LA; Macedo AVS; Manisty C; Ciardiello F; Farmakis D; de Boer RA; Skouri H; Suter TM; Cardinale D; Witteles RM; Fradley MG; Herrmann J; Cornell RF; Wechelaker A; Mauro MJ; Milojkovic D; de Lavallade H; Ruschitzka F; Coats AJS; Seferovic PM; Chioncel O; Thum T; Bauersachs J; Andres MS; Wright DJ; López-Fernández T; Plummer C; Lenihan D
    Eur J Heart Fail; 2020 Nov; 22(11):1945-1960. PubMed ID: 32463967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardio-oncology: Clinical and imaging perspectives for optimal cardiodetection and cardioprotection in patients with cancer.
    Thuny F; Huttin O; Ederhy S
    Arch Cardiovasc Dis; 2019 Oct; 112(10):550-558. PubMed ID: 31522992
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardio-Protective Therapy in Cardio-Oncology: Quo Vadis?
    Omland T
    Circulation; 2021 Aug; 144(9):667-669. PubMed ID: 34460325
    [No Abstract]   [Full Text] [Related]  

  • 15. Cardioprotection in cardio-oncology: a case for concern?
    Heusch G
    Cardiovasc Res; 2023 Oct; 119(12):e144-e145. PubMed ID: 37587745
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC).
    Čelutkienė J; Pudil R; López-Fernández T; Grapsa J; Nihoyannopoulos P; Bergler-Klein J; Cohen-Solal A; Farmakis D; Tocchetti CG; von Haehling S; Barberis V; Flachskampf FA; Čeponienė I; Haegler-Laube E; Suter T; Lapinskas T; Prasad S; de Boer RA; Wechalekar K; Anker MS; Iakobishvili Z; Bucciarelli-Ducci C; Schulz-Menger J; Cosyns B; Gaemperli O; Belenkov Y; Hulot JS; Galderisi M; Lancellotti P; Bax J; Marwick TH; Chioncel O; Jaarsma T; Mullens W; Piepoli M; Thum T; Heymans S; Mueller C; Moura B; Ruschitzka F; Zamorano JL; Rosano G; Coats AJS; Asteggiano R; Seferovic P; Edvardsen T; Lyon AR
    Eur J Heart Fail; 2020 Sep; 22(9):1504-1524. PubMed ID: 32621569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardio-Oncology in Childhood: State of the Art.
    Bennati E; Girolami F; Spaziani G; Calabri GB; Favre C; Parrini I; Lucà F; Tamburini A; Favilli S
    Curr Oncol Rep; 2022 Dec; 24(12):1765-1777. PubMed ID: 36181610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-Glucose Co-Transporter-2 Inhibitor Therapy During Anthracycline Treatment: Is There a Role for Cardioprotection?
    Khouri MG; Greene SJ
    JACC Heart Fail; 2022 Aug; 10(8):568-570. PubMed ID: 35902160
    [No Abstract]   [Full Text] [Related]  

  • 19. Genetics of Anthracycline-Associated Cardiotoxicity.
    Al-Otaibi TK; Weitzman B; Tahir UA; Asnani A
    Front Cardiovasc Med; 2022; 9():867873. PubMed ID: 35528837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonrandomized Real-World Evidence to Support Regulatory Decision Making: Process for a Randomized Trial Replication Project.
    Franklin JM; Pawar A; Martin D; Glynn RJ; Levenson M; Temple R; Schneeweiss S
    Clin Pharmacol Ther; 2020 Apr; 107(4):817-826. PubMed ID: 31541454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.